860352-01-8

Basic information

• Product Name: 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide
• Synonyms: 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide;5-(3-Fluorophenyl)-3-ureidothiophene-N-[(S)-piperidin-3-yl]-2-carboxamide;AZD 7762;White solid;1-(2-((S)-piperidin-3-ylcarbamoyl)-5-(3-fluorophenyl)thiophen-3-yl)urea;5-(3-Fluorophenyl)-3-ureidothiophene-N-[(S)-piperidin-3-yl]-2-carboxamide AZD 7762;AZD 7762 5-(3-Fluorophenyl)-3-ureidothiophene-N-[(S)-piperidin-3-yl]-2-carboxamide;(S)-5-(3-Fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide
• CAS NO: 860352-01-8
• Molecular Formula: C17H19FN4O2S.ClH
• Molecular Weight: 398.888
• Product Categories: api;Inhibitors
• Mol File: 860352-01-8.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 547.6 °C at 760 mmHg
• Flash Point: 285 °C
• Appearance: /
• Density: 1.38
• Storage Temp.: -20°
• Solubility: Soluble in DMSO (up to at least 25 mg/ml).
• PKA: 9.06±0.20(Predicted)
• Stability: Stable for 1 year as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
• CAS DataBase Reference: 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide(860352-01-8)
• EPA Substance Registry System: 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide(860352-01-8)

Safety Data

• Hazardous Substances Data: 860352-01-8(Hazardous Substances Data)

Usage

Description

3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide is a complex organic compound with a unique molecular structure that has potential applications in various fields, particularly in the pharmaceutical industry. Its chemical properties and interactions with biological systems make it a promising candidate for the development of new therapeutic agents.
Used in Pharmaceutical Industry:
3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide is used as a potential therapeutic agent for targeting specific biological pathways and processes. Its unique molecular structure allows it to selectively bind to and modulate the activity of certain proteins and enzymes, making it a valuable tool in the development of targeted drug therapies.
Used in Cancer Therapeutics:
In the field of cancer therapeutics, 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide is being studied for its ability to selectively inhibit the activity of checkpoint kinases (Chk) 1 and Chk2 by competitively and reversibly binding their respective ATP-binding sites. This selective inhibition can help to abrogate DNA damage-induced S and G2 checkpoints, thereby enhancing the efficacy of DNA-damage repair prohibitive agents such as gemcitabine and topotecan, both in vitro and in various tumor xenografts.
Used in Drug Delivery Systems:
To improve the delivery, bioavailability, and therapeutic outcomes of 3-[(Aminocarbonyl)amino]-5-(3-fluorophenyl)-N-(3S)-3-piperidinyl-2-Thiophenecarboxamide, researchers are developing novel drug delivery systems. These systems may involve the use of organic and metallic nanoparticles as carriers, allowing for more efficient and targeted delivery of the compound to specific cells or tissues within the body.

References

1) Zabludoff?et al.?(2008)?AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies; Mol. Cancer Ther.?7?2955 2) Mitchell?et al.?(2010)?In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762; Clin. Cancer Res.?16?2076 3) Morgan?et al. (2010)?Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair; Cancer Res.?70?49721 4) Lei?et al.?(2018)?Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells; Leuk. Res.?64?17 5) Ahmad?et al. (2015)?Identification of Ponatinib and Other Known Kinase Inhibitors with Potent MEKK2 Inhibitory Activity;?Biochem. Biophys. Res. Commun.?463?888 6) Park?et al.?(2018)?Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn; Biochem. Pharmacol.?154?270